ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
85,25
0,16%
Bitcoin
63 533,39
1,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) Actualités

VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DateHeureSourceTitreSymboleSociété
11/06/202412h00Business WireViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
10/06/202414h05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VRDNViridian Therapeutics Inc
06/06/202422h01Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
31/05/202414h00Business WireViridian Therapeutics Announces Participation in Upcoming June Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
10/05/202414h00Business WireViridian Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
08/05/202413h51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
08/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
08/05/202413h00Business WireViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
29/04/202414h00Business WireViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VRDNViridian Therapeutics Inc
05/03/202414h00Business WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:VRDNViridian Therapeutics Inc
28/02/202422h10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRDNViridian Therapeutics Inc
27/02/202422h01Business WireViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
16/02/202414h00Business WireViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal OfficerNASDAQ:VRDNViridian Therapeutics Inc
15/02/202402h28Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
14/02/202422h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
14/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
06/02/202422h01Business WireViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
24/01/202423h12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
19/01/202422h32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
18/01/202404h00Business WireViridian Therapeutics Announces Pricing of Public Offering of Shares of Common StockNASDAQ:VRDNViridian Therapeutics Inc
17/01/202422h01Business WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockNASDAQ:VRDNViridian Therapeutics Inc
08/01/202414h00Business WireViridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
04/01/202414h00Business WireViridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
18/12/202317h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
18/12/202313h00Business WireViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
08/12/202322h17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRDNViridian Therapeutics Inc
30/11/202322h05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VRDNViridian Therapeutics Inc
21/11/202314h00Business WireViridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VRDNViridian Therapeutics Inc
13/11/202322h01Business WireViridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
08/11/202314h00Business WireViridian Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN

Dernières Valeurs Consultées

NYSE
ECCV
Eagle Point Credit
BIT
P1TL14
BNP Paribas Issuance
TSXV
WBI
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés